Idiopathic Pulmonary Fibrosis Market, By Drug (Pirfenidone, Nintedanib, Others (Interferon gamma-1b and Others)), By Route of Administration (Oral, Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Phamacies), and By Geography (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa)

Published In : May 2023

Code : CMI2466

Pages :339

Formats :

Excel and PDF

Industry : Pharmaceutical

Idiopathic Pulmonary Fibrosis MarketSize and Trends

Global idiopathic pulmonary fibrosis market is estimated to be valued at US$ 3,853.6 million in 2022 and is expected to exhibit a CAGR of 8.7% during the forecast period (2022-2030).

Figure 1. Global Idiopathic Pulmonary Fibrosis Market Share (%), By Drug, 2022

Market Size and Trends

Increasing research and development activities by market players for the treatment of patients suffering from idiopathic pulmonary fibrosis

Increasing focus on research and development activities in idiopathic pulmonary fibrosis market by the key market players is expected to drive the market growth. Moreover, adoption of advanced technologies such as artificial intelligence platform, and increasing emerging strategies such as research and development activities and others in the markets can create favorable opportunities for the idiopathic pulmonary fibrosis market growth. For instance, in June 2021, Sunshine Lake Pharma Co., Ltd., a manufacturing company, announced the initiation of clinical trial to study the efficacy and safety of various doses of HEC585 Tablets with Pirfenidone in patients with idiopathic pulmonary fibrosis. This clinical trial is currently in phase 2.

Global Idiopathic Pulmonary Fibrosis Market- Driver

Increasing research and development activities by market players for the treatment of patients suffering from idiopathic pulmonary fibrosis